rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2006-2-2-4-8rpcardio-1012Research ArticleCLINICAL LECTURESКЛИНИЧЕСКИЕ ЛЕКЦИИSTROKE PREVENTION IN HYPERTENSIVE PATIENTSПРЕДУПРЕЖДЕНИЕ МОЗГОВОГО ИНСУЛЬТА У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙМарцевичС. Ю.MartsevichS. Y.ЕгоровВ. А.EgorovV. A.Государственный научно-исследовательский центр профилактической медицины РосздраваРоссияState Research Center of Preventive Medicine, RoszdravRussian Federation2006230120162248Copyright © Martsevich S.Y., Egorov V.A., 20162016Марцевич С.Ю., Егоров В.А.Martsevich S.Y., Egorov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1012

Importance of the stroke as one of the main reason of population mortality and invalidity is considered. Stroke risk factors including arterial hypertension are described. The main pharmacotherapy ways of primary and secondary stroke prevention are discussed.

Рассматривается значимость мозгового инсульта (МИ) как одной из основных причин смертности и инвалидизации населения. Приводятся факторы риска МИ, среди которых главную роль играет артериальная гипертония. Дается характеристика основным видам первичной и вторичной медикаментозной профилактики МИ.

мозговой инсультпервичная и вторичная медикаментозная профилактикаstrokeprimary and secondary pharmacotherapy preventionReferencesWarlow C., Sudlow C., Dennis M. et al. Stroke. Lancet 2003; 362: 1211-1224.Warlow C., Sudlow C., Dennis M. et al. Stroke. Lancet 2003; 362: 1211-1224.Ringelstein B., Nabavi D. Long-term prevention of ischaemic stroke and stroke recur-rence.Thrombosis Research 2000;98: V83-V96.Ringelstein B., Nabavi D. Long-term prevention of ischaemic stroke and stroke recur-rence.Thrombosis Research 2000;98: V83-V96.D’Agostinio R.B., Wolf P.A., Belanger A.J., Kannel W.B. Stroke risk profile: ad-justment for antihypertansive medication: the Framingham Study.Stroke 1994; 25:40-43.D’Agostinio R.B., Wolf P.A., Belanger A.J., Kannel W.B. Stroke risk profile: ad-justment for antihypertansive medication: the Framingham Study.Stroke 1994; 25:40-43.Guidelines Committee. 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension.J. Hypertension 2003; 21: 1011-1053.Guidelines Committee. 2003 European Society of HypertensionEuropean Society of Cardiology guidelines for the management of arterial hypertension.J. Hypertension 2003; 21: 1011-1053.Veterans Administration Co-operative Study Group. Effects of treatment on morbid-ity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-1034.Veterans Administration Co-operative Study Group. Effects of treatment on morbid-ity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202: 1028-1034.Julius S., Kjeldsen S., Weber M. et al. Outcomes in hypertensive patients at high car-diovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363 :2022-2031.Julius S., Kjeldsen S., Weber M. et al. Outcomes in hypertensive patients at high car-diovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363 :2022-2031.Dahlof B., Devereux R., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.Dahlof B., Devereux R., Kjeldsen S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 highrisk individuals. A randomised placebo-controlled trial. Lancet 2002;360:7-22.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 highrisk individuals. A randomised placebo-controlled trial. Lancet 2002;360:7-22.Di Napoli P., Taccardi A.A., Oliver M., De Caterina S. Statins and stroke: evidence for cholesterol-independent effects. Eur. Heart J. 2002;23:1908-1921.Di Napoli P., Taccardi A.A., Oliver M., De Caterina S. Statins and stroke: evidence for cholesterol-independent effects. Eur. Heart J. 2002;23:1908-1921.Furberg C. Natural statins and stroke risk. Circulation 1999; 99: 185-188.Furberg C. Natural statins and stroke risk. Circulation 1999; 99: 185-188.Sever P.S., Dahlof B., Poulter N.R. et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastain in patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Out-comes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.Sever P.S., Dahlof B., Poulter N.R. et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastain in patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Out-comes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.Pedersen T., Faergeman O., Kastelein J. High-dose atorvastatin vs usual-dose sim-vastatin for secondary prevention after myocardial infarction. JAMA 2005;294:2437-2445.Pedersen T., Faergeman O., Kastelein J. High-dose atorvastatin vs usual-dose sim-vastatin for secondary prevention after myocardial infarction. JAMA 2005;294:2437-2445.PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041.PROGRESS Collaborative Group. Randomised trial of a perindoprilbased blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041.Schrader J., Luders S., Kulshewski A. et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention. Stroke 2005;36:1218-1226.Schrader J., Luders S., Kulshewski A. et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention. Stroke 2005;36:1218-1226.

The authors declare that there are no conflicts of interest present.